Analysts expect Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to post $200,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Bellicum Pharmaceuticals’ earnings. The lowest sales estimate is $100,000.00 and the highest is $300,000.00. Bellicum Pharmaceuticals posted sales of $360,000.00 in the same quarter last year, which suggests a negative year-over-year growth rate of 44.4%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Bellicum Pharmaceuticals will report full-year sales of $3.63 million for the current financial year, with estimates ranging from $700,000.00 to $9.00 million. For the next financial year, analysts anticipate that the firm will report sales of $15.57 million, with estimates ranging from $1.30 million to $38.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.28. Bellicum Pharmaceuticals had a negative return on equity of 123.00% and a negative net margin of 6,729.02%. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.20 million.

Several equities analysts recently issued reports on BLCM shares. ValuEngine cut Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Zacks Investment Research cut Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 15th. Three equities research analysts have rated the stock with a sell rating and two have given a buy rating to the company’s stock. Bellicum Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $14.08.

Institutional investors and hedge funds have recently modified their holdings of the company. Knott David M lifted its position in shares of Bellicum Pharmaceuticals by 13.2% during the first quarter. Knott David M now owns 126,127 shares of the biopharmaceutical company’s stock worth $425,000 after acquiring an additional 14,700 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Bellicum Pharmaceuticals by 33.5% during the first quarter. ARK Investment Management LLC now owns 1,379,629 shares of the biopharmaceutical company’s stock valued at $4,649,000 after buying an additional 346,138 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Bellicum Pharmaceuticals during the first quarter valued at about $3,575,000. JPMorgan Chase & Co. grew its stake in shares of Bellicum Pharmaceuticals by 4.9% during the first quarter. JPMorgan Chase & Co. now owns 4,190,020 shares of the biopharmaceutical company’s stock valued at $14,120,000 after buying an additional 194,226 shares during the last quarter. Finally, Eagle Ridge Investment Management bought a new position in shares of Bellicum Pharmaceuticals during the first quarter valued at about $67,000. 54.90% of the stock is currently owned by institutional investors.

BLCM traded down $0.01 during trading hours on Wednesday, hitting $1.77. 330,371 shares of the stock were exchanged, compared to its average volume of 495,987. The stock has a 50-day simple moving average of $1.98. Bellicum Pharmaceuticals has a 12 month low of $1.52 and a 12 month high of $8.31. The firm has a market capitalization of $81.90 million, a PE ratio of -0.73 and a beta of 1.50. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.74 and a current ratio of 4.74.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.

Further Reading: What is meant by a buy rating?

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.